Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage ...
Read moreWOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage ...
Read moreFREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that ...
Read moreRESEARCH TRIANGLE PARK, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. GTHX, a commercial-stage ...
Read moreSANTA CLARA, Calif.--(BUSINESS WIRE)--Intevac, Inc. (Nasdaq: IVAC, “Intevac” or “the Company”), a leading supplier of thin-film ...
Read moreLA JOLLA, Calif.--(BUSINESS WIRE)--Sep 16, 2022--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in ...
Read moreSAN DIEGO, Sept. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, ...
Read moreMORRISVILLE, N.C., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant ...
Read moreBRISBANE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company ...
Read moreViridian Therapeutics, IncWALTHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the ...
Read morePARSIPPANY, N.J.--(BUSINESS WIRE)--IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on August 1, 2022, the Company ...
Read more© 2022 TheDailyStock.News